1.5 References

(Hyperlinks to references in text)

  1. De Bont R. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis. 2004;19(3):169–185.
  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74.
  3. Hanahan D, Weinberg RA, Francisco S. The Hallmarks of Cancer. Cell. 2000;100:57–70.
  4. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J cancer. 2010;127(12):2893–917.
  5. Piccirillo JF, Costas I, Reichman ME. Cancers of the Head and Neck. In: Ries L et al eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007:7–22.
  6. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
  7. J F et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fr Int Agency Res Cancer. 2013;http://globocan.iarc.fr. cited
  8. Blot WJ et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11):3282–7.
  9. Hashibe M et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99(10):777–89.
  10. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol biomarkers Prev. 2005;14(2):467–75.
  11. Anantharaman D et al. Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study. J Natl Cancer Inst. 2013;105(8):536–45.
  12. Kreimer AR et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31(21):2708–15.
  13. Rumboldt Z, Gordon L, Gordon L, Bonsall R, Ackermann S. Imaging in head and neck cancer. Curr Treat Options Oncol. 2006;7(1):23–34.
  14. Abraham J. Imaging for head and neck cancer. Surg Oncol Clin N Am. 2015;24(3):455–71.
  15. Knowles SM, Wu AM. Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology. J Clin Oncol. 2012;30(31). doi:10.1200/JCO.2012.42.4887
  16. Nimmagadda S, Ford EC, Wong JW, Pomper MG. Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol. 2008;18(2):136–48.
  17. Lambin P et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.
  18. Parmar C et al. Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer. Sci Rep. 2015;5(11044). doi:10.1038/srep11044
  19. De Ruysscher D. Predicting outcome by images?. Clin cancer Res. 2013;19(11):3334–3336.
  20. Rosenstein BS et al. Radiogenomics: radiobiology enters the era of big data and team science. Int J Radiat Oncol Biol Phys. 2014;89(4):709–13.
  21. O’Connor JPB et al. Imaging Biomarker Roadmap for Cancer Studies. Nat Rev Clin Oncol. 2016;in press(3):169–186.
  22. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57(1):39–43.
  23. Tanay A, Regev A. Scaling single-cell genomics from phenomenology to mechanism. Nature. 2017;541(7637):331–338.
  24. Collisson E a, Cho RJ, Gray JW. What are we learning from the cancer genome?. Nat Rev Clin Oncol. 2012;9(11):621–630.
  25. Ng SB et al. Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes. Nature. 2009;461(7261):272–276.
  26. Ezkurdia I et al. Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. Hum Mol Genet. 2014;23(22):5866–5878.
  27. Wouters BG. Proteomics: methodologies and applications in oncology. Semin Radiat Oncol. 2008;18(2):115–25.
  28. MacConaill LE. Existing and Emerging Technologies for Tumor Genomic Profiling. J Clin Oncol. 2013;31(15):1815–24.
  29. Guarnaccia M et al. Is this the real time for genomics?. Genomics. 2014;103(2–3):177–182.
  30. Garraway L a. Genomics-Driven Oncology: Framework for an Emerging Paradigm. J Clin Oncol. 2013;31(15):1806–14.
  31. Lockhart D, Winzeler E. Genomics, gene expression and DNA arrays. Nature. 2000;405(6788):827–836.
  32. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
  33. Morozova O, Marra MA. Applications of next-generation sequencing technologies in functional genomics. Genomics. 2008;92(5):255–264.
  34. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016;17(5):257–271.
  35. Lim LP, Lau NC, Garrett-engele P, Grimson A. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(2005):769–773.
  36. Friedman R, Farh K, Burge C, Bartel D. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
  37. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
  38. Bagga S et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122(4):553–63.
  39. Morozova N et al. Kinetic signatures of microRNA modes of action. RNA. 2012;1–21.
  40. Selbach M et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63.
  41. Begg AC. Molecular targeting and patient individualization. In: Joiner MC, van der Kogel AJ, editors. Basic Clinical Radiobiology. 4th edition. London: Hodder Arnold; 2010, p 324.
  42. Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature. 2013;500. doi:10.1038/nature12477
  43. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.
  44. Braakhuis BJM et al. Genetic Patterns in Head and Neck Cancers That Contain or Lack Transcriptionally Active Human Papillomavirus. JNCI J Natl Cancer Inst. 2004;96(13):998–1006.
  45. Slebos RJC et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin cancer Res. 2006;12(3 Pt 1):701–9.
  46. Seiwert TY et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632–641.
  47. Lawrence MS et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
  48. O’Sullivan B et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–451.
  49. Quon H, Forastiere AA. Controversies in Treatment Deintensification of Human Papillomavirus – Associated Oropharyngeal Carcinomas : Should We , How Should We , and for Whom. J Clin Oncol. 2013;31(5):5–7.
  50. Michmerhuizen NL, Birkeland AC, Bradford CR, Brenner JC. Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer. 2016;7(5–6):182–200.
  51. Poeta LM et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–61.
  52. Balz V et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 2003;63(6):1188–91.
  53. van der Riet P et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 1994;54(5):1156–8.
  54. Marsit CJ, Black CC, Posner MR, Kelsey KT. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin cancer Res. 2008;14(8):2371–7.
  55. Smeets SJ et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25(17):2558–64.
  56. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72.
  57. Sok JC et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006;12(17):5064–73.
  58. Temam S et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25(16):2164–70.
  59. Stransky N, Egloff A, Tward A. The mutational landscape of head and neck squamous cell carcinoma. Science (80- ). 2011;333(August):1157–1160.
  60. Agrawal N et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Sci NY. 2011;333(6046):1154–7.
  61. Lydiatt WM et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–137.
  62. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma–an update. CA Cancer J Clin. 2015;65(5):401–21.
  63. Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50.
  64. Henriques De Figueiredo B et al. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Eur J Cancer. 2016;65:109–112.
  65. Iyer NG et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599-607.
  66. Parsons JT et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94(11):2967–80.
  67. Howard J et al. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane database Syst Rev. 2016;12(12):CD010963.
  68. Parsons JT et al. Squamous cell carcinoma of the oropharynx: Surgery, radiation therapy, or both. Cancer. 2002;94(11):2967–2980.
  69. Berrington de Gonzalez A et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12(4):353–60.
  70. Piccirillo JF, Costas I. Cancer of the Larynx. In: Ries L et al eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2001:67–72
  71. Baujat B et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002026.
  72. Bourhis J et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–54.
  73. Garden AS et al. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(4):941–7.
  74. Chuang S-C et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J cancer. 2008;123(10):2390–6.
  75. Duprez F et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol. 2009;93(3):563–9.
  76. Adelstein DJ et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98.
  77. Trotti a. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1–12.
  78. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol. 2006;24(17):2636–43.
  79. Overgaard J et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933–40.
  80. So WKW et al. Quality-of-life among head and neck cancer survivors at one year after treatment–a systematic review. Eur J Cancer. 2012;48(15):2391–408.
  81. de Jong JM, van Daal WA, Elte JW, Hordijk GJ, Frölich M. Primary hypothyroidism as a complication after treatment of tumours of the head and neck. Acta Radiol Oncol. 1982;21(5):299–303.
  82. Wouters B, Begg AC. Irradiation-induced damage and the DNA damage response. In: Joiner M, van der Kogel AJ eds. Basic clinical radiobiology. London, UK: Hodder Arnold; 2009:11–26
  83. Bentzen SM, Joiner MC. The linear-quadratic approach in clinical practice. In: Joiner M, van der Kogel AJ eds. Basic clinical radiobiology. London: Hodder Arnold; 2006:120–134
  84. Egelmeer AGTM et al. Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiother Oncol. 2011;100(1):108–15.
  85. Lee WR et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42(5):1069–75.
  86. Murphy CT et al. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States. J Clin Oncol. 2015;34(2). doi:10.1200/JCO.2015.61.5906
  87. van Harten MC et al. Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol. 2015;51(3):272–278.
  88. Bernier J, Horiot J-C. Altered-fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol. 2012;24(3):223–8.
  89. Forastiere A a. et al. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer. JCO. 2013;31(7):845–52.
  90. Bonner J a et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.
  91. Pignon J-P, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
  92. Overgaard J et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46(2):135–46.
  93. Langendijk J a. et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiother Oncol. 2013;107(3):267–273.
  94. Molina M a et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients. Cancer. 2008;113(10):2797–806.
  95. Duffy S a et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol. 2009;27(12):1969–75.
  96. Le Tourneau C et al. Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head Neck. 2005;27(9):801–8.
  97. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61(4):1087–95.
  98. Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol (Madr). 2012;51(4):419–32.
  99. Jeremić B, Milicić B. Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol. 2009;32(2):163–8.
  100. van den Broek GB et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer. 2004;101(8):1809–17.
  101. Schroeff M et al. Prognosis: A variable parameter. Dynamic prognostic modeling in head and neck squamous cell carcinoma. Head Neck. 2012;(January):34–41.
  102. Bøje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma – A systematic review. Radiother Oncol. 2014 Jan;110(1):81-90.
  103. Gillison ML et al. Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer. J Clin Oncol. 2012;30(17):2102–11.
  104. Knegjens J, Hauptmann M. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck. 2011;33(3):375–382.
  105. Plataniotis G a et al. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004;59(4):1018–26.
  106. Kurek R et al. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlentherapie und Onkol. 2003;179(5):292–7.
  107. Tang C et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1514–20.
  108. Ballman K V. Biomarker: Predictive or prognostic?. J Clin Oncol. 2015;33(33):3968–3971.
  109. Andl T et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 1998;58(1):5–13.
  110. Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J cancer. 2007;121(8):1813–20.
  111. Fakhry C et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.
  112. Lassen P et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(12):1992–8.
  113. Ang KK et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
  114. Sørensen BS et al. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother Oncol. 2013;108(3):500–5.
  115. Rieckmann T et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 2013;107(2):242–6.
  116. O’Sullivan B et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–50.
  117. Marur S et al. E1308 : Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx — ECOG-ACRIN Cancer Research Group2016;35(5). doi:10.1200/JCO.2016.71.0681
  118. Begg AC. Molecular targeting and patient individualization. In: Joiner MC, van der Kogel AJ eds. Basic clinical radiobiology. London, UK: Hodder Arnold; 2009:316–331
  119. Withers HR. Cell cycle redistribution as a factor in multifraction irradiation. Radiology. 1975;114(1):199–202.
  120. Steel GG, McMillan TJ, Peacock JH. The 5Rs of radiobiology. Int J Radiat Biol Relat Stud Physics, Chem Med. 1989;56(6):1045–1048.
  121. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem Cells. 2010;28(4):639–648.
  122. Good JS, Harrington KJ. The Hallmarks of Cancer and the Radiation Oncologist: Updating the 5Rs of Radiobiology. Clin Oncol. 2013;25(10):1–9.
  123. Wright EA, Howard-Flanders P. The influence of oxygen on the radiosensitivity of mammalian tissues. Acta radiol. 1957;48(1):26–32.
  124. Howard-Flanders P, Moore D. The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen. I. A search for an effect of oxygen 0.02 second after pulsed irradiation. Radiat Res. 1958;9(4):422–37.
  125. Tinganelli W et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res. 2013;54 Suppl 1:i23–i30.
  126. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in Radiotherapy. Br J Radiol. 1953;26(312):638–648.
  127. Janssen HL, Haustermans KM, Balm a J, Begg a C. Hypoxia in head and neck cancer: how much, how important?. Head Neck. 2005;27(7):622–38.
  128. Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8(3):180–92.
  129. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87.
  130. Nordsmark M et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77(1):18–24.
  131. Brizel DM et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38(2):285–289.
  132. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41(1):31–9.
  133. Rischin D et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A Substudy of Trans-Tasman Radiation Oncolog. J Clin Oncol. 2006;24(13):2098–104.
  134. Eschmann SS et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260.
  135. Marcu LG, Bezak E, Filip SM. The role of PET imaging in overcoming radiobiological challenges in the treatment of advanced head and neck cancer. Cancer Treat Rev. 2012;38(3):185–93.
  136. Minagawa Y et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med. 2011;25(5):339–45.
  137. Bittner M et al. Exploratory geographical analysis of hypoxic subvolumes using 18 F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol. 2013 Sep;108(3):511-6.
  138. Hicks RJ et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32(12):1384–91.
  139. Fjeldbo CS et al. Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. Clin Cancer Res. 2016;22(16):4067–4076.
  140. Welsh L et al. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br J Cancer. 2017;116(1):28–35.
  141. Kaanders JHAM, Wijffels KIEM, Marres HAM, Raleigh JA, Kogel AJ Van Der. Pimonidazole Binding and Tumor Vascularity Predict for Treatment Outcome in Head and Neck Cancer. Cancer Res. 2002;62:7066–7074.
  142. Schrijvers ML et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(1):161–9.
  143. Koukourakis MI et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(5):1192–1202.
  144. Aebersold DM et al. Expression of Hypoxia-inducible Factor-1alpha: A Novel Predictive and Prognostic Parameter in the Radiotherapy of Oropharyngeal Cancer. Cancer Res. 2001;61:2911–2916.
  145. Koukourakis MI et al. Hypoxia-regulated Carbonic Anhydrase-9 ( CA9 ) Relates to Poor Vascularization and Resistance of Squamous Cell Head and Neck Cancer to Chemoradiotherapy. Clin cancer Res. 2001;7(11):3399–3403.
  146. De Schutter H et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer. 2005;5:42.
  147. Rademakers SE et al. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiother Oncol. 2013;108(3):517–522.
  148. Chi J-T et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3(3):e47.
  149. Winter SC et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007;67(7):3441–9.
  150. Buffa FM, Harris a L, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010;102(2):428–35.
  151. Eustace A et al. A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clin cancer Res. 2013;19(17):4879–88.
  152. Janssens GO et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30(15):1777–83.
  153. Toustrup K et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–31.
  154. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516–25.
  155. Begg a C et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol. 1999;50(1):13–23.
  156. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol (Madr). 1988;27(2):131–46.
  157. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16(3):831–43.
  158. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol. 1991;22(3):161–6.
  159. Fu KK et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.
  160. Bentzen SM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23(24):5560–7.
  161. Eriksen JG, Steiniche T, Overgaard J. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol (Madr). 2005;44(1):50–8.
  162. Pedicini P et al. Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol. 2012;7(1):143.
  163. Buffa FM et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin cancer Res. 2004;10(11):3745–54.
  164. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol. 2012;22(2):108–18.
  165. Tchou J et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol imaging Biol. 2010;12(6):657–62.
  166. Allal AS et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59(5):1295–300.
  167. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res. 1966;29(3):450–74.
  168. Sinclair W, Morton R. Variations in x-ray response during the division cycle of partially synchronized chinese hamster cells in culture. Nature. 1963;199:1158–60.
  169. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–42.
  170. Dobrowsky W et al. In vivo cell kinetic measurements in a randomized trial of continuous hyperfractionated accelerated radiotherapy with or without mitomycin c in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55(3):576–582.
  171. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys. 1988;15(3):575–9.
  172. Björk-Eriksson T, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys. 2000;46(1):13–9.
  173. West CM, Davidson SE, Roberts S a, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer. 1997;76(9):1184–90.
  174. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11(9):1699–707.
  175. Hedman M et al. Comparison of predicted and clinical response to radiotherapy: a radiobiology modelling study. Acta Oncol (Madr). 2009;48(4):584–90.
  176. Mitchell J, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer. 1987;(55):Suppl. VIII, 96-104.
  177. Diehn M et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780–783.
  178. Takata H et al. Chromatin Compaction Protects Genomic DNA from Radiation Damage. PLoS One. 2013;8(10):1–11.
  179. Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):1–14.
  180. Ramakrishnana N, Brennerb D. Predicting Individual Radiation Sensitivity: Current and Evolving Technologies. Radiat Res. 2008;170(5):666–675.
  181. Pollard JM, Gatti R a. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys. 2009;74(5):1323–31.
  182. Lomax ME, Folkes LK, O’Neill P. Biological consequences of radiation-induced DNA damage: Relevance to radiotherapy. Clin Oncol. 2013;25(10):578–585.
  183. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma R a. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
  184. Morgan M a., Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res. 2015;21(13):2898–2904.
  185. Dillon MT, Good JS, Harrington KJ. Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin Oncol. 2014;26(5):257–65.
  186. Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015;16(6):329–344.
  187. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592–603.
  188. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231–237.
  189. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59(7):1391–1399.
  190. Skinner HD et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012;18(1):290–300.
  191. Baumann M, Krause M, Thames H, Trott K, Zips D. Cancer stem cells and radiotherapy. Int J Radiat Biol. 2009;85(5):391–402.
  192. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin cancer Res. 2011;17(23):7224–9.
  193. Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2016;In press. doi:10.1016/j.addr.2016.02.002
  194. Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9(5):351–360.
  195. Brown JM. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br J Radiol. 2014;87:20130686.
  196. Kioi M et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694–705.
  197. Siva S, MacManus MP, Martin RF, Martin O a. Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82–90.
  198. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879–880.
  199. Golden EB et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803.
  200. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2(October):1–7.
  201. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85.
  202. Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell. 2015;27(4):437–438.
  203. Sullivan LB, Gui DY, Heiden MG Vander. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer. 2016;16(11):680–693.
  204. Giaccia a. J. Molecular Radiobiology: The State of the Art. J Clin Oncol. 2014;32(26):2871-8.
  205. Martens-de Kemp SR et al. DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells. PLoS One. 2013;8(4). doi:10.1371/journal.pone.0061555
  206. Mandic R et al. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin cancer Res. 2005;11(19 Pt 1):6845–52.
  207. Weidhaas JB et al. The KRAS -Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. JAMA Oncol. 2017;3(4):483.
  208. Rampias T et al. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res. 2014;20(11):2933–46.
  209. Psyrri A et al. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin cancer Res. 2014;20(11):3023–32.
  210. De Roock W et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.
  211. Hall S, Groome PA, Irish J, O’Sullivan B. TNM-based stage groupings in head and neck cancer: Application in cancer of the hypopharynx. Head Neck. 2009;31(January):1–8.
  212. Groome P a et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer. 2001;92(6):1484–94.
  213. Groome P a et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol. 2002;55(6):533–44.
  214. Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck. 2001;23(8):613–24.
  215. Baumann M et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16(4):234–249.
  216. Begg AC, Stewart F a, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–253.
  217. Grégoire V, Jeraj R, Lee JA, O’Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: Conformal, tailored, and adaptive?. Lancet Oncol. 2012;13(7):e292–e300.